EMG
APLS

ETF Managers Group’s Apellis Pharmaceuticals APLS Stock Holding History

ETF Managers Group’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-12,899
Closed -$818K – 675
2021
Q2 		$818K Buy
+12,899
New +$666K 0.01% 289

Other funds holding APLS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ETF Managers Group's APLS Position: Q3 2021 in Review

ETF Managers Group sold out of Apellis Pharmaceuticals (APLS) in Q3 2021, closing a stake of 12,899 shares — an estimated $818K sold.

ETF Managers Group first reported a position in APLS in Q2 2021 and held it in 1 quarter. The position peaked at $818K in Q2 2021. 181 funds tracked by Wall St. Rank hold APLS as of Q3 2021.

  • ETF Managers Group reported no remaining Apellis Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • ETF Managers Group sold 12,899 Apellis Pharmaceuticals shares in Q3 2021, an estimated $818K.
  • ETF Managers Group first reported a position in Apellis Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • ETF Managers Group's Apellis Pharmaceuticals position peaked at $818K in Q2 2021.
  • 181 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2021.

Based on ETF Managers Group's 13F filing for Q3 2021, filed 15 Nov 2021.